Adverse effects of GLP-1 receptor agonists: difference between revisions
Diff·revision 2 → 3·03:47, 9 Jul 2024
Difference between revision 2 and revision 3 of Adverse effects of GLP-1 receptor agonists. 11 lines changed; the page grew by 733 bytes.
| Revision 2 — 21:35, 2 Jul 2024 Chromatokid (talk) expand §Body composition and other effects 1,312 bytes ±0 | Revision 3 — 03:47, 9 Jul 2024 ArchiveBot (talk) bot: sort category members 2,045 bytes +733 | ||
|---|---|---|---|
| 10 | Their mechanism is receptor-level rather than route-level: the same effects occur with an orally administered small-molecule agonist, which argues against a local gastrointestinal irritation explanation. Delayed [[Gastric emptying|gastric emptying]] and area postrema signalling are the proposed contributors.{{r|drucker2018}} | 10 | Their mechanism is receptor-level rather than route-level: the same effects occur with an orally administered small-molecule agonist, which argues against a local gastrointestinal irritation explanation. Delayed [[Gastric emptying|gastric emptying]] and area postrema signalling are the proposed contributors.{{r|drucker2018}} |
| 11 | 11 | ||
| + | 12 | == Gastrointestinal effects == | |
| + | 13 | | Effect | Approximate frequency at higher doses | Course | | |
| + | 14 | |---|---|---| | |
| + | 15 | | Nausea | 30–45% | Peaks in escalation, declines | | |
| + | 16 | | Vomiting | 20–25% | Follows nausea | | |
| + | 17 | | Diarrhoea | 25–30% | Variable | | |
| + | 18 | | Constipation | 20–25% | May persist | | |
| + | 19 | ||
| + | 20 | Frequencies are from placebo-controlled trials and the placebo arms are not zero — nausea is reported by 10–20% of placebo participants in the same trials, so the attributable excess is smaller than the raw figure.{{r|wilding2021}} | |
| + | 21 | ||
| 12 | == References == | 22 | == References == |
| 13 | {{reflist}} | 23 | {{reflist}} |
| 14 | <ref name="drucker2018">Drucker DJ. "Mechanisms of action and therapeutic application of glucagon-like peptide-1." ''Cell Metabolism'' 27(4):740–756 (2018). PMID 29617641.</ref> | 24 | <ref name="drucker2018">Drucker DJ. "Mechanisms of action and therapeutic application of glucagon-like peptide-1." ''Cell Metabolism'' 27(4):740–756 (2018). PMID 29617641.</ref> |
| + | 25 | <ref name="wilding2021">Wilding JPH, Batterham RL, Calanna S, et al. "Once-weekly semaglutide in adults with overweight or obesity." ''New England Journal of Medicine'' 384(11):989–1002 (2021). PMID 33567185.</ref> | |
| 15 | 26 | ||
| 16 | {{DEFAULTSORT:Adverse effects of GLP-1 receptor agonists}} | 27 | {{DEFAULTSORT:Adverse effects of GLP-1 receptor agonists}} |